Corinne Goldsmith Dickinson Center for Multiple Sclerosis

Rady Children's Hospital Successfully Pioneers Portal Vein Thrombosis Procedure Opening Up New Possibilities in Pediatric Care

Retrieved on: 
Tuesday, April 4, 2023
Quality of life, Esophagus, Portal vein, Pain, MRI, Patient, SAN, Child, Portal vein thrombosis, Gastrointestinal bleeding, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Hospital, Nursing, Birth control, Medical imaging, Rady Children's Hospital

Dr. Henri Justino , interventional cardiologist at Rady Children's Hospital, developed a hands-on approach to treatment with a technique called portal vein recanalization.

Key Points: 
  • Dr. Henri Justino , interventional cardiologist at Rady Children's Hospital, developed a hands-on approach to treatment with a technique called portal vein recanalization.
  • The minimally invasive procedure involves advancing a small wire and then a balloon-tipped catheter to the portal vein to dig through the blockage.
  • "Portal vein recanalization is yet another innovative way that we at Rady Children's can provide children a better quality of life.
  • Two centers – the Dickinson Center at Rady Children's and a Texas institution – are currently using portal vein recanalization to treat pediatric portal vein thrombosis.

EQS-News: Immunic to Participate in Investor and Scientific Conferences in November and December

Retrieved on: 
Friday, November 11, 2022
Private Securities Litigation Reform Act, Stanford University, CET, DHODH, Risk, U.S. Securities and Exchange Commission, ISI, Lead, Nasdaq, Regeneration, Webcast, Royal Adelaide Hospital, Department, Multiple sclerosis, COVID-19, Stanford University School of Medicine, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Doctor of Philosophy, Institute, SEC, Annual report, Degenerative disease, Saunders family, CA, Time, Evercore, Drug development, CRO, Mount Sinai Hospital, Clinical trial, Conference, Psoriasis, University, NEW, Pediatrics, Security (finance), Icahn School of Medicine at Mount Sinai, Society, Metabolism, APSA, Pharmaceutical industry, Genetics, Neurology, The Immune Response Corporation

Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access.

Key Points: 
  • Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access.
  • An archived replay of the webcast will be available on the Events and Presentations section of Immunics website at: ir.imux.com/events-and-presentations .
  • Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in investor and scientific conferences.
  • Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Immunic to Participate in Investor and Scientific Conferences in November and December

Retrieved on: 
Thursday, November 10, 2022
Private Securities Litigation Reform Act, Stanford University, DHODH, CET, Risk, U.S. Securities and Exchange Commission, ISI, Lead, Regeneration, Webcast, Royal Adelaide Hospital, Department, Multiple sclerosis, Stanford University School of Medicine, COVID-19, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Doctor of Philosophy, Institute, SEC, Annual report, Degenerative disease, Saunders family, CA, Time, Evercore, Drug development, Mount Sinai Hospital, Clinical trial, Conference, Psoriasis, University, University of Münster, Pediatrics, Security (finance), Icahn School of Medicine at Mount Sinai, Society, Metabolism, APSA, Pharmaceutical industry, Vaccine, Genetics, Neurology, The Immune Response Corporation

Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access.

Key Points: 
  • Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access.
  • An archived replay of the webcast will be available on the "Events and Presentations" section of Immunic's website at: ir.imux.com/events-and-presentations .
  • Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will participate in a fireside chat at this conference in New York on Thursday, December 1, 2022 at 12:30 pm ET.
  • Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in investor and scientific conferences.

New Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live with Relapsing Multiple Sclerosis: COBRA study presented at the 7th Congress of the European Academy of Neurology (EAN)

Retrieved on: 
Tuesday, June 22, 2021
Biotechnology, Other Health, Health, Pharmaceutical, Clinical trials, Medical specialties, Medicine, Glatiramer acetate, Immunology, Multiple sclerosis, Breastfeeding, Immunosuppressants, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Multiple sclerosis drug pipeline, the Study, COPAXONE®, Teva, THE STUDY, COPAXONE®, TEVA

The COBRA study used data from the National German Multiple Sclerosis and Pregnancy Registry from 2011 to 2020.

Key Points: 
  • The COBRA study used data from the National German Multiple Sclerosis and Pregnancy Registry from 2011 to 2020.
  • Patients were eligible for the study if they were diagnosed with relapsing MS (RMS), gave a live birth, were breastfeeding under GA treatment (Copaxone 20 or 40 mg/mL) or breastfeeding under no DMT treatment.
  • Real-world safety of Copaxone in Offspring of Breastfeeding and Treated Relapsing Multiple Sclerosis (RMS) pAtients (COBRA study) was retrospective data analysis using the national German Multiple Sclerosis and Pregnancy Registry.
  • Al, Safety analysis of offspring breastfed by mothers on glatiramer acetate therapy for relapsing multiple sclerosis; presented at EAN 2021.

Hadassah Medical Center and Neurogenesis Announce Groundbreaking Results from a Phase 2 Study in Progressive Multiple Sclerosis treated with NG-01 Autologous Cells Therapy

Retrieved on: 
Tuesday, December 8, 2020
Clinical research, Design of experiments, Placebo-controlled study, Multiple sclerosis, Medical research, Medical specialties, Medicine, Immunosuppressants, Corinne Goldsmith Dickinson Center for Multiple Sclerosis

"The treatment was well tolerated and the trial met all of its primary endpoints," said Professor Dimitrios Karussis, lead principle investigator and Director of MS Center at Hadassah Medical Center, Jerusalem.

Key Points: 
  • "The treatment was well tolerated and the trial met all of its primary endpoints," said Professor Dimitrios Karussis, lead principle investigator and Director of MS Center at Hadassah Medical Center, Jerusalem.
  • "Progressive MS is a chronic, debilitating disease with no satisfactory treatment to improve or reverse established disability," said Tal Gilat, CEO of NeuroGenesis.
  • The Phase 2, randomized, double-blind, placebo-controlled, clinical trial assessed the safety, tolerability and efficacy of transplantation of NG-01 in people with progressive MS.
  • The Company's lead product is NG-01 for the treatment of progressive Multiple Sclerosis, (in which a placebo-controlled Phase 2 study has been completed and recently published).

InnoCare Announces Clearance by the US FDA of Phase II Clinical Trial Using orelabrutinib for the Treatment of Multiple Sclerosis

Retrieved on: 
Monday, November 2, 2020
FDA, Pharmaceutical, Health, Clinical trials, Medical specialties, Clinical medicine, Multiple sclerosis, Medicine, Autoimmune diseases, Multiple Sclerosis International Federation, Monoclonal antibodies, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Multiple sclerosis research

This will be a randomized, double-blind, placebo-controlled and multi-center phase II Study in Relapsing-Remitting multiple sclerosis patients (RRMS), which will be conducted in the US and several European countries.

Key Points: 
  • This will be a randomized, double-blind, placebo-controlled and multi-center phase II Study in Relapsing-Remitting multiple sclerosis patients (RRMS), which will be conducted in the US and several European countries.
  • According to the Multiple Sclerosis International Federation (MSIF), more than 2.8 million people around the world are affected by MS today1.
  • I am very delighted to learn the swift IND clearance by the US FDA, and we are initiating the phase II clinical trial immediately, said Dr. Jasmine Cui, the co-founder, chairman, and Chief Executive Officer of InnoCare.
  • Currently, multi-center, multi-indication clinical trials are underway in the US and China with orelabrutinib as monotherapy or in combination therapies.

Bristol Myers Squibb Announces Interim Results from Long-Term Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis

Retrieved on: 
Tuesday, September 1, 2020
Research, Infectious diseases, Clinical trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Multiple sclerosis, Organ systems, Medical specialties, Clinical medicine, Autoimmune diseases, Myelin, Ozanimod, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Multiple sclerosis research, DAYBREAK, Multiple Sclerosis, Zeposia (ozanimod), Bristol Myers Squibb

Multiple sclerosis (MS) is a disease in which the immune system attacks the protective myelin sheath that covers the nerves.

Key Points: 
  • Multiple sclerosis (MS) is a disease in which the immune system attacks the protective myelin sheath that covers the nerves.
  • Approximately 85% of patients are initially diagnosed with RMS, compared with 10-15% with progressive forms of the disease.
  • The U.S. Food and Drug Administration (FDA) approved Zeposia for the treatment of adults with relapsing forms of multiple sclerosis (RMS) in March 2020.
  • These risks, assumptions, uncertainties and other factors include, among others, that future study results will be consistent with the results to date.

 Atara Biotherapeutics Announces First Patient Enrolled in Randomized Placebo-Controlled Study of Allogeneic T-cell Therapy ATA188 in Progressive Forms of Multiple Sclerosis

Retrieved on: 
Wednesday, June 17, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Clinical research, Design of experiments, Health, Medical research, Placebo-controlled study, Clinical trial, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Amatuximab, Multiple Sclerosis (MS), EBV in MS, ATA188, Atara Biotherapeutics, Inc.

The Phase 1b study ( NCT03283826 ) is a double-blind randomized placebo-controlled study evaluating the efficacy and safety of ATA188.

Key Points: 
  • The Phase 1b study ( NCT03283826 ) is a double-blind randomized placebo-controlled study evaluating the efficacy and safety of ATA188.
  • We are thrilled at the investigator and patient interest in our randomized placebo-controlled Phase 1b study assessing the efficacy and safety of ATA188, said AJ Joshi, MD, Senior Vice President and Chief Medical Officer of Atara Biotherapeutics.
  • All subjects will have the opportunity to enter into a three-year open-label extension after the first two years of treatment.
  • Atara is advancing a Phase 1 ATA188 clinical study in patients with progressive MS across clinical sites in the U.S. and Australia.

DGAP-News: Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19

Retrieved on: 
Monday, June 15, 2020
Medical specialties, Medicine, Health, Immunosuppressants, Colitis, Diarrhea, RTT, Ulcerative colitis, Clinical trial, Tcelna, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, IMU-838, Immunic, Inc.

Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19

Key Points: 
  • Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
    The issuer is solely responsible for the content of this announcement.
  • Patients will be enrolled at 10 to 35 centers in Germany, the United States and a half dozen European countries.
  • It is a prospective, multicenter, randomized, placebo-controlled, double-blind clinical trial in patients with moderate COVID-19, designed to evaluate efficacy, safety and tolerability of IMU-838.
  • IMU-838 is in phase 2 clinical development for COVID-19, relapsing-remitting multiple sclerosis and ulcerative colitis, with an additional phase 2 trial considered in Crohn's disease.

NeurologyLive® and the Consortium of Multiple Sclerosis Centers Partner to Host Virtual Annual Meeting

Retrieved on: 
Tuesday, April 28, 2020
Technology, Other Communications, Publishing, Communications, Software, Other Health, Biotechnology, Internet, Managed care, Health, Multiple sclerosis, Organ systems, Autoimmune diseases, Neurological disorders, Medical specialties, Management of multiple sclerosis, Nervous system, Corinne Goldsmith Dickinson Center for Multiple Sclerosis

The CMSC Annual Meeting brings together multiple sclerosis (MS) thought leaders to learn about cutting-edge research findings, clinical advances and emerging care issues.

Key Points: 
  • The CMSC Annual Meeting brings together multiple sclerosis (MS) thought leaders to learn about cutting-edge research findings, clinical advances and emerging care issues.
  • Throughout the four-day meeting, expert faculty will virtually deliver educational sessions and presentations addressing topics including management of MS, pharmacotherapeutics, hot topics in MS and comprehensive care.
  • Attendees can earn up to 18 contact hours of continuing education over the course of the meeting.
  • The Consortium of Multiple Sclerosis Centers (CMSC) is the largest North American multidisciplinary membership organization dedicated to defining and advancing the standard of care of MS patients.